Zobrazeno 1 - 10
of 22 987
pro vyhledávání: '"first line"'
Autor:
Miaoyan Wei, Rujiao Liu, Yunyun Xu, Xiaobing Chen, Chao Liu, Xueli Bai, Xiaochen Zhang, Shuiping Gao, Jialin Li, Zhen Sheng, Jianpo Lian, Wenliang Wang, Jian Zhang, Si Shi, Jin Xu, Xianjun Yu
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-11 (2024)
Abstract Background Chemotherapy remains the standard first-line treatment for pancreatic adenocarcinoma, but with limited efficacy. We aimed to explore the feasibility of adding the PARP inhibitor fuzuloparib to mFOLFIRINOX in the locally advanced/m
Externí odkaz:
https://doaj.org/article/cef3d052c08f444f99a82d9527d12961
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1065-1079 (2024)
Abstract Introduction The therapeutic arsenal for psoriatic arthritis (PsA) is gradually being expanded, but the use of these targeted treatments must be optimal. Our objective was to guide the choice of targeted therapy to use as first-line treatmen
Externí odkaz:
https://doaj.org/article/4e833a8b91f949be94ac8797615e1b5b
Autor:
Dana M. Chase, Soham Shukla, Julia Moore, Tirza Areli Calderón Boyle, Jonathan Lim, Jessica Perhanidis, Jean A. Hurteau, Jeanne M. Schilder
Publikováno v:
Oncology and Therapy, Vol 12, Iss 3, Pp 599-607 (2024)
Abstract Introduction Niraparib first-line maintenance (1LM) therapy has demonstrated clinical benefit for patients with ovarian cancer (OC) in clinical trial and real-world settings, but data on factors associated with real-world patient outcomes re
Externí odkaz:
https://doaj.org/article/877785eaaff34eb1860b79fe8e83b988
Autor:
Jing Zhang, Pei-Yuan Lv, Xiao Zhao, Ming-Lu Liu, Lu-Peng Qiu, Zi-Zhong Yang, Sheng-Jie Sun, Guo-Qing Zhang
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background This study aimed to evaluate the effectiveness and safety of recombinant human endostatin (Rh-endostatin) plus programmed cell death 1 (PD-1) inhibitors and chemotherapy as first-line treatment for advanced or metastatic non-small
Externí odkaz:
https://doaj.org/article/5454b9a09a4d4af499f7dd40fb5f4407
Autor:
Huiling Shi, Yong Tan, Chao Ma, Yushan Wei, Fengling Shi, Juan Wang, Caihua Xu, Rongrui Liang
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
ObjectiveTo evaluate the efficacy and safety of various first-line initial treatment systemic regimens for patients with unresectable esophageal squamous carcinoma(ESCC), utilizing a network meta-analysis approach.MethodsA comprehensive search for ra
Externí odkaz:
https://doaj.org/article/a617cf45871f41d4bb4b7bec68744912
Autor:
Urska Janzic, Natalie Maimon Rabinovich, Walid Shalata, Waleed Kian, Katarzyna Szymczak, Rafal Dziadziuszko, Marko Jakopovic, Giannis Mountzios, Adam Pluzanski, Antonio Araujo, Andriani Charpidou, Sameh Daher, Abed Agbarya
Publikováno v:
Current Oncology, Vol 31, Iss 8, Pp 4369-4381 (2024)
ROS1 rearrangements are considered rare in non-small-cell lung cancer (NSCLC). This retrospective real-world study aimed to evaluate first-line treatment with crizotinib, a tyrosine kinase inhibitor (TKI) standard of care vs. new generation ROS1 anti
Externí odkaz:
https://doaj.org/article/adb21f604fcc4328811acd70c304e952
Autor:
Bobbie Rimel, Tirza Areli Calderón Boyle, Sara Burns, Jonathan Lim, John Hartman, Linda Kalilani, Jeanne M. Schilder, Jean A. Hurteau, Amanda Golembesky
Publikováno v:
Oncology and Therapy, Vol 12, Iss 3, Pp 465-475 (2024)
Abstract Introduction Clinical trials have demonstrated prolonged survival associated with niraparib first-line maintenance (1LM) therapy, compared with placebo, for patients with ovarian cancer (OC). However, data are limited on real-world 1LM nirap
Externí odkaz:
https://doaj.org/article/be7e5d732cdc4346b5c2c634f5e5b807
Autor:
Erika FJORDKVIST, Maria HÄLLEBERG NYMAN, Madeleine WINBERG, Eva JOELSSON-ALM, Ann Catrine ELDH
Publikováno v:
BMC Health Services Research, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background First-line managers have a unique role and potential in encouraging the use of evidence-based clinical practice guidelines (CPGs) and thus serve the provision of safe patient care. In acute and planned hospital care, effective yet
Externí odkaz:
https://doaj.org/article/e5b9e189c5ef4411b2e54df68fee3f22
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-17 (2024)
Abstract Objective To evaluate the safety of first-line systemic therapy for metastatic colorectal cancer through network meta-analysis. Methods The literature from PubMed, Embase, Web of Science, and Cochrane Library databases was searched from the
Externí odkaz:
https://doaj.org/article/bb588319a20f4114900138c95442de8f
Autor:
Ekaterina N. Ozhmegova, Anna I. Kuznetsova, Aleksey V. Lebedev, Anastasia A. Antonova, Kristina V. Kim, Yana M. Munchak, Alexander S. Tumanov, Elena V. Kazennova
Publikováno v:
Вопросы вирусологии, Vol 69, Iss 3, Pp 231-240 (2024)
Introduction. The amino acid substitution A62V in reverse transcriptase was identified as a mutation correlated with virologic failure in patients on first-line therapy including tenofovir (TDF) and tenofovir alafenamide (TAF). A62V is a typically po
Externí odkaz:
https://doaj.org/article/a8187a788f214b16be4a375a2b9c6ad1